We bring innovation to multiple indications
We have a robust pipeline of future products
with a current focus on burns, diabetic foot ulcers and breast cancer applications.
Revolutionizing diagnosTICS &
therapeuticS INTO A THERANOSTIC PLATFORM
We have developed and patented a revolutionary Biomarker which targets necrotic tissue i.e dead cells. Necrosis only occurs in pathological conditions including burns, skin wounds, cardiovascular diseases and is prevalent in the core of about 80% of all solid tumours.
Imaging and quantifying the amount of necrotic tissue in cancer provides us with a new diagnostic platform, as the amount of necrosis indicates the location and aggressiveness of a tumour.
Our biomarker will also deliver therapies precisely at the core of tumours and the percentage increase in necrotic volume this causes, indicates the efficacy of those therapies.
The combination of necrosis based diagnostics and targeted therapy forms the basis of our new theranostic platform.
MECHANISM OF ACTION at the cellular level
Our Biomarker is a very bright near Infrared Fluorescent
compound that specifically binds to dead cells.
LIVE CELL
Necrotic Dead Cell
Burn wound is visualized by NecroSense (in green) in an ex vivo human skin sample (autofluorescence of healthy skin in red)
NecroSense
Biomarker imaging burns & chronic skin wounds
DIAGNOSIS
Surgeons can distinguish between healthy and necrotic tissue
SURGERY
Enables real time visualization of dead tissue during debridement surgery
HEALING
Accurate debridement will give better attachment of the skin graft and prevents rejection due to necrosis-induced inflammation
PATIENT EXPERIENCE
Shortens operations with less morbidity and annuls re-operations due to necrosis-induced rejection
NecroSense Application
NecroPET
Radioactive biomarker for diagnosis & treatment of solid tumours
Screening
Indicates the presence of a serious disease
Diagnosis
Determines the aggressiveness of the tumor
Therapy efficacy
Validates the efficacy of anticancer therapy
SURGERY
Real time visualization of tumor tissue ensuring complete resection
Treatment
Delivers therapeutics accurately
NecroPet ApplicationS
Rapid Screening & Diagnosis
Rapid monitoring Therapy Efficacy
Image Guided Surgery
Accurate & Complete
Therapy
Targeted & Precise
Our team
Experienced. Committed.
ROBERT BRETON
Co-Founder & CEO
20 years Executive Experience
Lean Startups
Investor relations
Board Mandates
HERB HEYNEKER
Co-Founder & Member of Advisory Board
Board of Directors of US and Dutch companies
Advisor to various biotech startups
+ 50 peer-reviewed papers
+ 30 US patents
PROF. Dr. CLEMENS LOWIK
Scientific Advisor
Prof Optical Molecular Imaging
Co-founder of several Startups
7 Patents
Founder & President of ESMI
GERARD KRIELEN
Member of Advisory Board
Study Chartered Accountant completed in 1993
25 years of CFO experience
Financing and M&A transactions
Private Investor in Medical Startups
DR. MIRRE DE NOO
Medical Advisor
Managing director Reggeborgh Medical
Surgeon at Equipe healthcare companies
Member of the Supervisory Board of the Population Screening North
LOEKI SCHAEFFERS
Strategy & Sustainability Advisor
Expert on Market Transformation, Circular Economy, Sustainability Transitions and Programme Management.
Founder of InterconnACT
JULIETTE BORDET
Business Development & Marketing Manager
PharmD.
Specialised Master in Biopharmaceutical
Management at ESCP Europe
Experiences in Startup and Medical Devices Industries
Latest
TKI-LSH Health Holland collaborative project granted!
PanaceAR, Semi-Finalist at EIT Health Catapult
